SCHEMBL2235019

SCHEMBL2235019

O=C(CCCCl)c1ccc(Cl)cc1

nearest known ligand 0.63

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GSK3B P49841 2/20 0.63
NPC1 O15118 5/20 0.52
RAB9A P51151 4/20 0.52
KMT2A Q03164 3/20 0.50
MEN1 O00255 2/20 0.50
SMN1; SMN2 Q16637 1/20 0.50
HSD17B10 Q99714 1/20 0.50
ERCC5 P28715 1/20 0.50
FEN1 P39748 1/20 0.50
DRD2 P14416 2/20 0.49
HTR1A P08908 1/20 0.49
HTR2A P28223 1/20 0.49
HTR2C P28335 1/20 0.49
HTR7 P34969 1/20 0.49
HRH1 P35367 1/20 0.49
DRD3 P35462 1/20 0.49
HTR2B P41595 1/20 0.49
HSD11B1 P28845 1/20 0.49
MAPT P10636 3/20 0.48
L3MBTL1 Q9Y468 2/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27570052 0.94 GSK3B (0.57) GSK3BNPC1RAB9AKMT2AMEN1
SCHEMBL5660844 0.94 GSK3B (0.61) GSK3BNPC1RAB9AKMT2AMEN1
SCHEMBL5662338 0.92 GSK3B (0.59) GSK3BNPC1RAB9AKMT2AMEN1
SCHEMBL5660040 0.92 GSK3B (0.59) GSK3BNPC1RAB9AKMT2AMEN1
SCHEMBL6609685 0.89 MMP1 (0.63) GSK3BNPC1KMT2AMEN1MAPT
SCHEMBL9712507 0.87 GSK3B (0.68) GSK3BNPC1RAB9AKMT2AMEN1
SCHEMBL653535 0.87 GSK3B (0.68) GSK3BNPC1RAB9AKMT2AMEN1
SCHEMBL6610011 0.84 MMP1 (0.61) GSK3BNPC1KMT2AMEN1MAPT
SCHEMBL16552727 0.84 GSK3B (0.70) GSK3BNPC1RAB9AKMT2AMEN1
SCHEMBL862889 0.83 NPC1 (0.76) NPC1RAB9AL3MBTL1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 75 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-115335374-B GLP-1R modulating compounds 吉利德科学公司 2025-05-27 CN disclosed
US-20250099431-A1 GLP-1R MODULATING COMPOUNDS GILEAD SCIENCES, INC. 2025-03-27 US disclosed
EP-4523751-A2 GLP-1R MODULATING COMPOUNDS Gilead Sciences, Inc. (US) 2025-03-19 EP disclosed
EP-4097097-B1 GLP-1R MODULATING COMPOUNDS GILEAD SCIENCES INC (US) 2025-01-15 EP disclosed
US-12121511-B2 GLP-1R modulating compounds GILEAD SCIENCES, INC. (US) 2024-10-22 US disclosed
CN-115335374-A GLP-1R modulating compounds 吉利德科学公司 2022-11-11 CN disclosed
US-20220288030-A1 GLP-1R MODULATING COMPOUNDS GILEAD SCIENCES, INC. 2022-09-15 US disclosed
US-20220288030-A1 GLP-1R MODULATING COMPOUNDS GILEAD SCIENCES, INC. 2022-09-15 US disclosed
EP-3683222-B1 NOVEL BICYCLIC OR TRICYCLIC HETEROCYCLIC COMPOUND MITSUBISHI TANABE PHARMA CORP (JP) 2021-10-06 EP disclosed
WO-2021154796-A1 GLP-1R MODULATING COMPOUNDS GILEAD SCIENCES, INC. (US) 2021-08-05 WO disclosed
US-4921528-A PLANT GROWTH REGULATORS, FUNGICIDES BAYER AKTIENGESELLSCHAFT (DE) 1990-05-01 US disclosed
US-4870088-A ANIMALS AND PLANTS HOECHST AKTIENGESELLSCHAFT (DE) 1989-09-26 US disclosed
EP-0237917-A2 1,1-Disubstituted cyclopropane derivatives, processes for their preparation and their use HOECHST AKTIENGESELLSCHAFT (DE) 1987-09-23 EP disclosed
EP-0180850-A2 Antimycotic azolyl-methyl-cyclopropyl-carbinol derivatives BAYER AG (DE) 1986-05-14 EP disclosed
EP-0180136-A2 Substituted azolylmethyl-cyclopropyl carbinol derivatives BAYER AG (DE) 1986-05-07 EP disclosed
US-4515793-A PARASITICIDES EDNA MCCONNELL CLARK FOUNDATION (US) 1985-05-07 US disclosed
US-4372953-A Tetrazole derivatives, and anti-ulcer composition containing the same OTSUKA PHARMACEUTICAL COMPANY, LIMITED (JP) 1983-02-08 US disclosed
US-4358457-A ANTICONVULSANTS, ANALGESICS, AND MUSCLE RELAXANTS MERRELL DOW PHARMACEUTICALS INC. (US) 1982-11-09 US disclosed
US-4045568-A FUNGICIDES, BACTERICIDES, ANTIPROTOZOA AGENTS SYNTEX (U.S.A.) INC. (US) 1977-08-30 US disclosed
US-3979444-A CENTRAL NERVOUS SYSTEM DEPRESSANTS, HYPOTENSIVES THE UPJOHN COMPANY (US) 1976-09-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12121511-B2 GLP-1R modulating compounds GLP1R, GIPR, GPR119 GSK3B 485/4885NPC1 1254/4885RAB9A 460/4885
US-20250099431-A1 GLP-1R MODULATING COMPOUNDS GLP1R, GIPR, GPR119 GSK3B 485/4885NPC1 1254/4885RAB9A 460/4885
US-20220288030-A1 GLP-1R MODULATING COMPOUNDS GLP1R, GIPR, GPR119 GSK3B 485/4885NPC1 1254/4885RAB9A 460/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.